WO2011136161A1 - 内耳障害の予防又は治療薬 - Google Patents
内耳障害の予防又は治療薬 Download PDFInfo
- Publication number
- WO2011136161A1 WO2011136161A1 PCT/JP2011/060025 JP2011060025W WO2011136161A1 WO 2011136161 A1 WO2011136161 A1 WO 2011136161A1 JP 2011060025 W JP2011060025 W JP 2011060025W WO 2011136161 A1 WO2011136161 A1 WO 2011136161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inner ear
- drugs
- disorders
- hearing loss
- medicament according
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the present invention relates to a medicament for preventing or treating inner ear disorders, which comprises a compound having an aldose reductase inhibitory action as an active ingredient.
- Inner ear disorder refers to a disorder that is frequently caused by inner ear deafness, inner ear deafness, inner ear tinnitus, and inner ear dizziness.
- Inner ear hearing loss develops due to aging, disease, genetic factors, noise, or the like.
- Inner ear tinnitus is a phenomenon in which sound is perceived even when there is no sound source in the external world.
- Inner ear vertigo has severe rotational vertigo, often accompanied by nausea, vomiting, and tinnitus.
- adenosine triphosphate disodium for the purpose of improving inner ear circulation disorders, and improvement of internal lymphedema
- a diuretic such as isosorbide
- hyperbaric oxygen therapy or stellate ganglion block therapy
- the spirohydantoin derivative represented by the general formula (I) is a compound having an aldose reductase (AR) inhibitory action (Non-patent Document 1).
- Non-patent Document 1 diabetic complication
- patent document 2 circulatory system disease
- patent document 3 diabetic simple retinopathy
- patent document 4 diabetic simple retinopathy
- Diabetic keratopathy (patent document 5), diabetic macular disease (patent document 6), severe diabetic retinopathy (patent document 7), cardiac dysfunction or myocardial disorder (patent document 8), acute renal failure (patent document 9)
- each document describes uses as a cerebral ischemia or cerebral ischemia / reperfusion injury in stroke (Patent Document 10) and a protective agent for retinal nerve or optic nerve (Patent Document 11).
- no use for inner ear disorders has been reported.
- JP 61-200991 A Japanese Patent Laid-Open No. 4-173791 JP-A-6-135968 Japanese Patent Laid-Open No. 7-242547 JP-A-8-231549 International Publication No. 2005/072066 International Publication No. 2005/079792 International Publication No. 2006/090699 International Publication No. 2007/069727 International Publication No. 2007/097301 International Publication No. 2008/093691
- the present inventors evaluated the effect of the spirohydantoin derivative represented by the general formula (I) on inner ear disorders. As a result, the present inventors have found that the compound is effective for reducing the function of the auditory brainstem response (ABR) and detaching hair cells inside the cochlea. That is, according to the present invention, it is possible to provide a preventive or therapeutic agent for inner ear disorders containing the spirohydantoin derivative represented by the general formula (I) as an active ingredient.
- ABR auditory brainstem response
- X represents a halogen atom or a hydrogen atom
- R 1 and R 2 represent a hydrogen atom or an optionally substituted C 1-6 alkyl group simultaneously or separately.
- Examples of the spirohydantoin derivative represented by the general formula (I) include (2S, 4S) -6-fluoro-2 ', 5'-dioxospiro [chroman-4,4'-imidazolidine] -2-carboxamide (hereinafter referred to as phyllamide). Dalestat) is preferred.
- Inner ear disorders include inner ear deafness, inner ear tinnitus, and inner ear dizziness.
- Inner ear hearing loss may include sensorineural hearing loss and mixed hearing loss.
- the compound of the present invention can be administered in combination with other drugs used for inner ear disorders.
- other drugs used for inner ear disorders include steroid drugs, anticholinergics, antihistamines, antiviral drugs, leukotriene receptor antagonists, anticoagulants, vasodilators, thrombolytic drugs, vitamin B, Examples include vitamin B derivatives and inner ear circulation improving agents, and can be combined with one or more of these.
- a medicament for preventing or treating inner ear disorders can be provided.
- the highly safe drug therapy which can be taken for a long period of time can be provided.
- a mouse hyperacoustic model the effect after one week with respect to the increase in an auditory brainstem response (ABR) threshold when fidarestat is administered prophylactically is shown.
- ABR auditory brainstem response
- the effect after 2 weeks on the increase of the auditory brainstem response (ABR) threshold when fidarestat is administered prophylactically is shown.
- the effect after one week on the increase in the auditory brainstem response (ABR) threshold when fidarestat, prednisolone, or both are therapeutically administered is shown.
- the effect after 2 weeks on the increase in the auditory brainstem response (ABR) threshold when fidarestat, prednisolone, or both are therapeutically administered is shown.
- the inhibitory effect of fidarestat on the increase of the outer hair cell shedding rate inside the cochlea is shown.
- the inhibitory effect of fidarestat on the loss of outer hair cells due to gentamicin loading is shown.
- the active ingredient of the medicament of the present invention is a spirohydantoin derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof. All are known compounds, and can be produced according to the synthesis method described in JP-A-63-057588.
- X in the formula represents a halogen atom or a hydrogen atom, preferably a halogen atom such as a fluorine atom.
- R 1 and R 2 in the formula represent a hydrogen atom or an optionally substituted C 1-6 alkyl group simultaneously or separately, preferably a hydrogen atom.
- C 1-3 alkyl groups are preferred.
- compounds in which X is a fluorine atom and R 1 and R 2 are hydrogen atoms are particularly preferable.
- the pharmacologically acceptable salt of the spirohydantoin derivative is preferably a pharmaceutically acceptable salt in view of its use.
- Specific examples include pharmacologically acceptable inorganic and organic base salts such as sodium, lithium, potassium, magnesium, ammonium, quaternary ammonium salts, diethylamine, and diethanolamine. These salts can be easily obtained, for example, by treating a spirohydantoin derivative represented by the general formula (I) with a base.
- the medicament of the present invention is a medicament for preventing or treating inner ear disorders.
- inner ear disorders include inner ear deafness, inner ear tinnitus, and inner ear dizziness.
- Inner ear disorder means that the inner ear is damaged for some reason.
- the inner ear is located at the back of the ear, and the mammalian inner ear consists of the cochlea, the vestibule and the semicircular canal.
- causes of the occurrence of inner ear disorders include circulatory disorders, metabolic disorders, or inflammation (infections). In terms of tissue, hair cell loss and degeneration, and edema due to abnormal circulation of the inner ear lymph are observed. Because the inner ear contains organs responsible for hearing and balance, such as hearing loss, tinnitus, dizziness, nystagmus, lightheadedness, ear pain, ear tightness, voice emphasis, or hearing hypersensitivity With symptoms / findings.
- Hearing loss occurs due to aging, disease, genetic factors, or noise. From the cause of the disorder, it is classified into transmission hearing loss, sensorineural hearing loss, and mixed hearing loss that combines both transmission hearing loss and sensorineural hearing loss.
- Conductive hearing loss occurs when an organ that transmits vibrations is inflamed due to injury to the outer or middle ear.
- Sensorineural hearing loss occurs because the cochlea in the inner ear that determines the vibration of the sound is damaged, and the sensory cells are impaired or nerves are impaired when signals are sent from the sensory cells to the brain. It also occurs when the hair cells inside the cochlea are reduced by nerve destruction or aging for some reason.
- inner ear hearing loss is usually sensorineural hearing loss or mixed hearing loss.
- Sensorineural deafness includes sudden deafness, viral deafness, drug-induced deafness due to side effects such as antibiotics, anticancer drugs, or diuretics, noise-induced deafness, and explosion caused by strong noise over a long period
- side effects such as antibiotics, anticancer drugs, or diuretics
- noise-induced deafness and explosion caused by strong noise over a long period
- the inner ear deafness is not limited by the cause of the occurrence, and it means that hearing is reduced due to a disorder in the inner ear and sound and voice cannot be heard well, and includes sensorineural hearing loss and mixed hearing loss.
- Inner ear tinnitus is a phenomenon in which sound is perceived even when there is no sound source in the outside world.
- Inner ear hearing loss is often accompanied by tinnitus, and protection of the inner ear from inner ear hearing loss leads to prevention of tinnitus.
- Inner ear vertigo often has severe rotational vertigo, often accompanied by nausea / vomiting and tinnitus. Benign paroxysmal positional vertigo and Meniere's disease are also included in inner ear vertigo.
- the organ that controls hearing (cochlea) and the organ that controls balance (the vestibule of the inner ear) that are related to dizziness are originally developed and differentiated from the same organ, and are in the same place or very close to each other. Easy to affect. For this reason, inner ear disorders often involve tinnitus and dizziness in addition to symptoms of hearing loss. Therefore, it is considered that the improvement of the inner ear disorder is effective for hearing loss, tinnitus, and dizziness.
- the dose of the compound represented by the general formula (I), which is the active ingredient of the medicament of the present invention varies depending on symptoms, age, administration method, dosage form, etc. Usually, 0.1 mg to 450 mg, preferably 1 mg to 300 mg per day is administered once or in several divided doses every day.
- the medicament of the present invention is formulated into tablets, capsules, powders, granules, solutions, syrups, injections, or ear drops by a conventional formulation technique.
- the formulated medicament can be administered orally or parenterally.
- pharmacologically acceptable excipients for formulation such as starch, lactose, purified sucrose, glucose, crystalline cellulose, carboxycellulose, carboxymethylcellulose, carboxyethylcellulose, calcium phosphate, magnesium stearate And gum arabic can be used.
- a lubricant, a binder, a disintegrant, a coating agent, a coloring agent, and the like can be blended.
- stabilizers, solubilizers, suspending agents, emulsifiers, buffers, preservatives, and the like can be used.
- the medicament of the present invention can be administered in combination with other medicaments or therapies used for inner ear disorders.
- the other drugs that can be combined include steroid drugs, anticholinergics, antihistamines, antiviral drugs, leukotriene receptor antagonists, anticoagulants, vasodilators, thrombolytic drugs, vitamin B and its derivatives, Or an inner ear circulation improvement drug etc. are mentioned, These 1 or more types can be combined.
- Other drugs used for the above-mentioned inner ear disorders are administered mainly for the purpose of improving blood circulation in the inner ear.
- the effect of each medicament can be enhanced.
- the dose and administration period of steroid drugs are clinically limited due to side effects.
- the combination with the medicament of the present invention has a great advantage in terms of safety and effectiveness, such as enabling early withdrawal from a steroid drug.
- Hyperbaric oxygen therapy refers to therapy that sends oxygen throughout the body by inhaling oxygen in an atmosphere of atmospheric pressure higher than atmospheric pressure, and aims to improve blood flow.
- Stellate ganglion block therapy refers to a treatment method that blocks the stellate ganglion, temporarily paralyzes the function of the sympathetic nerve, and increases the function of the parasympathetic nerve.
- the active ingredients may be contained in separate preparations as a plurality of preparations, or the same preparation as one preparation May be included.
- a pharmaceutical consisting of a combination is a pharmaceutical in which a plurality of pharmaceuticals or active ingredients thereof are administered in combination. Multiple medicaments or active ingredients thereof are preferably administered to the patient substantially simultaneously.
- the present invention is not necessarily limited to the case where the plurality of preparations are administered simultaneously.
- the administration may be the same number of times or may be different.
- the dosage of other drugs used for inner ear disorders varies depending on the drug.
- the dosage of the steroid drug is usually 0.1 mg to 500 mg per day or divided into several times.
- Anticholinergic drugs, antihistamines, antiviral drugs, leukotriene receptor antagonists, anticoagulants, vasodilators, thrombolytic drugs, vitamin B, vitamin B derivatives, and inner ear circulation improving drugs are prescribed for each drug. It is preferred to administer according to the usual usage and dosage.
- the spirohydantoin derivative represented by the general formula (I), which is an active ingredient of the medicament of the present invention is a compound having an aldose reductase (AR) inhibitory action, it has an AR inhibitory action and an effect of preventing or treating inner ear disorders. Implications are suggested.
- ranirestat AS-3201
- ARI-809 CP-744809
- epalrestat epalrestat
- zopolrestat epalrestat
- zenarestat tolrestat
- imirestat ponalstat
- boglistat [5- (3- And thienyl) tetrazol-1-yl] acetic acid monohydrate (TAT)
- M-160209 M-160209
- SG-210 SG-210
- NZ-314 NZ-314
- fidarestat was selected from the compounds of the general formula (I) and tested. However, these do not limit the present invention, and may be changed without departing from the spirit of the present invention.
- the hair cells are detached by inner hair cells (inner hair cells; inner hair cells arranged in one row are indicated as IHC) and outer hair cells (outer hair cells; outer hair cells arranged in three rows. (Indicated as OHC1,2,3 from the inside) by pathological evaluation. This was performed by analysis (Fisher test as a post-hoc test).
- There were 5 groups, n 6), and ABR was performed on 6 patients in each group. Fidarestat was fed for 2 weeks after the strong acoustic load. Prednisolone was orally administered once after a strong acoustic load.
- Fidarestat shows the increase in auditory brainstem response (ABR) threshold seen by strong acoustic load, either 1 week or 2 weeks after strong acoustic load. Was also significantly suppressed (FIGS. 1-4). That is, Fidarestat showed a preventive effect and a therapeutic effect against an ABR threshold increase due to a strong acoustic load.
- the Fidarestat 32 mg / kg / day administration group showed the same effect as the prednisolone 1 mg / kg / day administration, and the combination administration group showed a significant inhibitory effect compared to the prednisolone administration group. It was.
- Fidarestat was found to have a significant protective effect against the increase in the auditory brainstem response (ABR) threshold and the rate of loss of outer hair cells inside the cochlea after hypersonic activity. The cochlear pathological and auditory functional effects were consistent.
- fidarestat is effective for inner ear disorders such as inner ear deafness, inner ear dizziness, and inner ear tinnitus. Furthermore, the effect was comparable to the effect of prednisolone, a steroid agent commonly used in inner ear disorders. Moreover, it was shown that the combined use of fidarestat and prednisolone further enhances the effect compared to the case of single administration. With regard to steroid drugs such as prednisolone, the withdrawal method has become a problem in terms of clinical side effects. From the results of this study, it can be said that fidarestat is also useful as a maintenance therapy after withdrawal of steroid drugs. As described above, fidarestat is effective in preventing or treating inner ear disorders.
- the culture medium used was Dulbecco's modified eagles medium (DMEM solution) containing 10% fetal bovine serum, HEPES (250 mM), penicillin G (30 U / l), and conditions of 37 ° C., 5% CO 2 and 95% humidity. Cultured under.
- DMEM solution Dulbecco's modified eagles medium
- HEPES 250 mM
- penicillin G 30 U / l
- 37 ° C., 5% CO 2 and 95% humidity Cultured under.
- fidarestat is effective for the prevention or treatment of drug-induced inner ear disorders due to side effects such as antibiotics, anticancer agents, or diuretics.
- Fidarestat is considered to be effective for inner ear disorders regardless of the cause because it has been confirmed to be effective not only for strong acoustic inner ear disorders but also for drug-induced inner ear disorders. It is done.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
(1)本発明の医薬と、他の医薬と、を両方含む単一製剤の投与、
(2)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の同一投与経路での同時投与、
(3)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の同一投与経路での時間差をおいての投与、
(4)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の異なる投与経路での同時投与、
(5)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の異なる投与経路での時間差をおいての投与、
(6)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の同一投与経路での異なる投与間隔における投与、及び、
(7)本発明の医薬と、他の医薬と、を別々に製剤化して得られる2種以上の製剤の異なる投与経路での異なる投与間隔における投与が挙げられる。
試験方法
実験はマウス強大音響モデルを用いて評価した。これは、強大音響に暴露されることによる内耳障害モデルであり、B6マウス(Slc,雌,8週令で実験開始)に強大音響(128 dB SPL(sound pressure level:音圧レベル)を4時間負荷して作製した。強大音響負荷の直前に、聴性脳幹反応(ABR:auditory brainstem response)閾値を測定した(pre値)。4時間の負荷を行ってから1週後及び2週後にABRを測定した。予防実験については、2週後のABR閾値を測定後、内耳を摘出し、蝸牛内部にある内有毛細胞と外有毛細胞と呼ばれる2種類の有毛細胞の脱落について病理評価できるよう固定した。有毛細胞の脱落は、内有毛細胞(inner hair cell ;1列に並ぶ内有毛細胞をIHCとして表示)及び外有毛細胞(outer hair cell ;3列に並ぶ外有毛細胞について、内側から各々OHC1,2,3として表示)を病理評価することにより行った。検定は、分散分析(post-hoc testとしてFisher test)で実施した。
動物は、強大音響群(コントロール群、n=10)、強大音響+フィダレスタット32mg/kg/day投与群(フィダレスタット投与群、n=10)の2群とし、ABRは各群10例について、病理評価は各群5例について実施した。なお、フィダレスタットは強大音響負荷の2日前から音響負荷後2週間目まで混餌投与した。
動物は、強大音響群(コントロール群、n=6)、強大音響+フィダレスタット8mg/kg/day投与群、32mg/kg/day投与群(フィダレスタット投与群、n=6)、強大音響+プレドニゾロン1mg/kg/day投与群(プレドニゾロン投与群、n=6)、強大音響+プレドニゾロン1mg/kg/day投与+フィダレスタット32mg/kg/day投与群(併用投与群、n=6)の5群とし、ABRを各群6例について実施した。なお、フィダレスタットは強大音響負荷後から2週間まで混餌投与した。プレドニゾロンは強大音響負荷後に1回、経口投与した。
(1)聴性脳幹反応(ABR)閾値の増加に対する効果
フィダレスタットは、強大音響負荷によってみられる聴性脳幹反応(ABR)閾値の増加を、強大音響負荷の1週後及び2週後のどちらにおいても有意に抑制した(図1-4)。即ち、フィダレスタットは、強大音響負荷によるABR閾値増加に対して、予防効果及び治療効果を示した。また、治療効果において、フィダレスタット32mg/kg/day投与群ではプレドニゾロン1mg/kg/day投与と同等の効果がみられ、しかも、併用投与群ではプレドニゾロン投与群よりも有意な抑制効果が見られた。
フィダレスタットは、強大音響負荷2週後に観察された外有毛細胞の脱落率増加を有意に抑制した(図5)。
内耳障害に対する有効性評価で汎用されているマウス強大音響モデルを用いて、フィダレスタットの内耳障害に対する効果を検討した。音響性障害モデルは、フリーラジカル、活性酸素、及びホスホリパーゼA2が関与する炎症性モデルであり、ステロイド薬の有効性が知られている。フィダレスタットは、強大音響後に見られる聴性脳幹反応(ABR)閾値の増加、蝸牛内部の外有毛細胞の脱落率の増加に対し、有意な保護効果が確認された。また、蝸牛内病理的効果と聴覚機能的効果は一致する結果であった。このような内耳の保護作用を有することは、フィダレスタットが、内耳性難聴、内耳性めまい及び内耳性耳鳴等の内耳障害に有効であることを示している。さらにその効果は、内耳障害で汎用されるステロイド剤であるプレドニゾロンの効果と匹敵するものであった。その上、フィダレスタットとプレドニゾロンとを併用すると、それぞれ単独投与の場合よりさらに効果が増強することが示された。プレドニゾロン等のステロイド薬については、離脱法が臨床的副作用の面で課題となっているが、本試験結果から、フィダレスタットはステロイド薬の離脱後の維持療法剤としても有用であるといえる。以上より、フィダレスタットは内耳障害の予防又は治療に有効である。
試験方法
3-5日齢のSD系ラットから蝸牛を摘出後、lateral wallをはずした後、基底回転コルチを採取した。一晩コルチ器を培養した後に、ゲンタマイシン(35μg)とともにフィダレスタットの各濃度(0、0.05、0.1、0.2、0.5、1、2μM)を添加した培養液にて48時間培養した。培養後、4%パラホルムアルデヒドで固定した。尚、培養液には10%fetal bovine serum、HEPES(250mM)、ペニシリンG(30U/l)を含むDulbecco’s modified eagles medium(DMEM溶液)を用い、37℃、5%CO2、湿度95%の条件下で培養した。
ゲンタマイシン負荷による外有毛細胞消失率はコントロール群で50%であったが、フィダレスタット投与群は0.1μMから有意に抑制し、0.5μM以上の消失率は25%であった(図6)。即ち、0.5μM以上では75%の外有毛細胞が生存していた。
薬剤性内耳障害に対する有効性評価で汎用されているゲンタマイシン負荷外有毛細胞消失モデルを用いて、フィダレスタットの薬剤性内耳障害に対する効果を検討した。その結果、フィダレスタットは、低濃度からゲンタマイシン負荷による有毛細胞の脱落を抑制し、有効性が確認された。つまり、フィダレスタットは、抗生剤、抗がん剤、又は利尿剤などの副作用による薬剤性内耳障害の予防又は治療に有効である。以上のように、強大音響性内耳障害のみならず、薬剤性内耳障害に対しても有効性が確認されたことから、フィダレスタットは、原因の如何を問わず内耳障害に有効であると考えられる。
Claims (6)
- 一般式(I)で示されるスピロヒダントイン誘導体が(2S,4S)-6-フルオロ-2',5'-ジオキソスピロ[クロマン-4,4'-イミダゾリジン]-2-カルボキサミドである、請求項1に記載の医薬。
- 前記内耳障害が、内耳性難聴、内耳性耳鳴、及び内耳性めまいからなる群より選択される、請求項1又は2に記載の医薬。
- 前記内耳性難聴が、感音難聴又は混合性難聴である、請求項3に記載の医薬。
- 内耳障害に用いられる他の医薬との組み合わせから構成される、請求項1~4のいずれかに記載の医薬。
- 前記内耳障害に用いられる他の医薬が、ステロイド薬、抗コリン薬、抗ヒスタミン薬、抗ウイルス薬、ロイコトリエン受容体拮抗薬、抗凝固薬、血管拡張薬、血栓溶解薬、ビタミンB、ビタミンB誘導体、及び内耳循環改善薬からなる群から選択される少なくとも1種である、請求項5に記載の医薬。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127030432A KR20130086143A (ko) | 2010-04-28 | 2011-04-25 | 내이장애의 예방 또는 치료약 |
AU2011246232A AU2011246232A1 (en) | 2010-04-28 | 2011-04-25 | Prophylactic or therapeutic medication for inner ear disorders |
CN2011800213017A CN102884067A (zh) | 2010-04-28 | 2011-04-25 | 内耳障碍的预防或治疗药 |
EP11774942.4A EP2565196A4 (en) | 2010-04-28 | 2011-04-25 | PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR INTERNAL EAR DISORDERS |
US13/583,707 US20130005698A1 (en) | 2010-04-28 | 2011-04-25 | Pharmaceutical for preventing or treating an inner ear disorder |
CA2791360A CA2791360A1 (en) | 2010-04-28 | 2011-04-25 | A pharmaceutical for preventing or treating an inner ear disorder |
JP2012512827A JPWO2011136161A1 (ja) | 2010-04-28 | 2011-04-25 | 内耳障害の予防又は治療薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-102780 | 2010-04-28 | ||
JP2010102780 | 2010-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011136161A1 true WO2011136161A1 (ja) | 2011-11-03 |
Family
ID=44861461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/060025 WO2011136161A1 (ja) | 2010-04-28 | 2011-04-25 | 内耳障害の予防又は治療薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130005698A1 (ja) |
EP (1) | EP2565196A4 (ja) |
JP (1) | JPWO2011136161A1 (ja) |
KR (1) | KR20130086143A (ja) |
CN (1) | CN102884067A (ja) |
AU (1) | AU2011246232A1 (ja) |
CA (1) | CA2791360A1 (ja) |
WO (1) | WO2011136161A1 (ja) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61200991A (ja) | 1985-03-04 | 1986-09-05 | Sanwa Kagaku Kenkyusho:Kk | スピロ―3―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤 |
JPS6357588A (ja) | 1986-08-28 | 1988-03-12 | Sanwa Kagaku Kenkyusho Co Ltd | ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤 |
US4783486A (en) * | 1987-01-16 | 1988-11-08 | American Home Products Corporation | Tolrestat for hearing impairment |
JPH04173791A (ja) | 1990-11-07 | 1992-06-22 | Sanwa Kagaku Kenkyusho Co Ltd | 循環器系疾患の予防及び治療剤 |
JPH04364166A (ja) * | 1990-02-21 | 1992-12-16 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジン化合物を含有する内耳微小循環改善剤 |
JPH06135968A (ja) | 1992-10-27 | 1994-05-17 | Sanwa Kagaku Kenkyusho Co Ltd | ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤 |
JPH07242547A (ja) | 1994-03-02 | 1995-09-19 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿病性単純網膜症の進行阻止剤乃至治療剤 |
JPH08231549A (ja) | 1994-12-28 | 1996-09-10 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿病性角膜症の治療剤 |
JP2004137256A (ja) * | 2002-08-22 | 2004-05-13 | Mitsubishi Pharma Corp | 内耳障害の予防及び/又は治療のための医薬 |
WO2004045603A1 (ja) * | 2002-11-21 | 2004-06-03 | Nichimo Co., Ltd. | 突発性難聴治療用の医薬組成物 |
WO2005072066A2 (ja) | 2004-01-30 | 2005-08-11 | Sanwa Kagaku Kenkyusho Co | 糖尿病黄斑症の予防又は治療剤 |
WO2005079792A1 (ja) | 2004-02-20 | 2005-09-01 | Sanwa Kagaku Kenkyusho Co., Ltd. | 重症糖尿病網膜症の予防又は治療剤 |
WO2006090699A1 (ja) | 2005-02-22 | 2006-08-31 | Sanwa Kagaku Kenkyusho Co., Ltd. | 虚血又は虚血再灌流によって起こる心機能障害若しくは心筋障害の予防又は治療剤 |
WO2007069727A1 (ja) | 2005-12-16 | 2007-06-21 | Sanwa Kagaku Kenkyusho Co., Ltd. | 急性腎不全の予防または治療剤 |
WO2007097301A1 (ja) | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤 |
WO2008093691A1 (ja) | 2007-01-31 | 2008-08-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | 網膜神経又は視神経の保護剤 |
WO2009103755A1 (en) * | 2008-02-19 | 2009-08-27 | Dsm Ip Assets B.V. | Novel use of 3,3'-diindolylmethane |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105864A1 (en) * | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
-
2011
- 2011-04-25 EP EP11774942.4A patent/EP2565196A4/en not_active Withdrawn
- 2011-04-25 AU AU2011246232A patent/AU2011246232A1/en not_active Abandoned
- 2011-04-25 JP JP2012512827A patent/JPWO2011136161A1/ja active Pending
- 2011-04-25 US US13/583,707 patent/US20130005698A1/en not_active Abandoned
- 2011-04-25 CN CN2011800213017A patent/CN102884067A/zh active Pending
- 2011-04-25 WO PCT/JP2011/060025 patent/WO2011136161A1/ja active Application Filing
- 2011-04-25 CA CA2791360A patent/CA2791360A1/en not_active Abandoned
- 2011-04-25 KR KR1020127030432A patent/KR20130086143A/ko not_active Application Discontinuation
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61200991A (ja) | 1985-03-04 | 1986-09-05 | Sanwa Kagaku Kenkyusho:Kk | スピロ―3―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤 |
JPS6357588A (ja) | 1986-08-28 | 1988-03-12 | Sanwa Kagaku Kenkyusho Co Ltd | ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤 |
US4783486A (en) * | 1987-01-16 | 1988-11-08 | American Home Products Corporation | Tolrestat for hearing impairment |
JPH04364166A (ja) * | 1990-02-21 | 1992-12-16 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジン化合物を含有する内耳微小循環改善剤 |
JPH04173791A (ja) | 1990-11-07 | 1992-06-22 | Sanwa Kagaku Kenkyusho Co Ltd | 循環器系疾患の予防及び治療剤 |
JPH06135968A (ja) | 1992-10-27 | 1994-05-17 | Sanwa Kagaku Kenkyusho Co Ltd | ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤 |
JPH07242547A (ja) | 1994-03-02 | 1995-09-19 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿病性単純網膜症の進行阻止剤乃至治療剤 |
JPH08231549A (ja) | 1994-12-28 | 1996-09-10 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿病性角膜症の治療剤 |
JP2004137256A (ja) * | 2002-08-22 | 2004-05-13 | Mitsubishi Pharma Corp | 内耳障害の予防及び/又は治療のための医薬 |
WO2004045603A1 (ja) * | 2002-11-21 | 2004-06-03 | Nichimo Co., Ltd. | 突発性難聴治療用の医薬組成物 |
WO2005072066A2 (ja) | 2004-01-30 | 2005-08-11 | Sanwa Kagaku Kenkyusho Co | 糖尿病黄斑症の予防又は治療剤 |
WO2005079792A1 (ja) | 2004-02-20 | 2005-09-01 | Sanwa Kagaku Kenkyusho Co., Ltd. | 重症糖尿病網膜症の予防又は治療剤 |
WO2006090699A1 (ja) | 2005-02-22 | 2006-08-31 | Sanwa Kagaku Kenkyusho Co., Ltd. | 虚血又は虚血再灌流によって起こる心機能障害若しくは心筋障害の予防又は治療剤 |
WO2007069727A1 (ja) | 2005-12-16 | 2007-06-21 | Sanwa Kagaku Kenkyusho Co., Ltd. | 急性腎不全の予防または治療剤 |
WO2007097301A1 (ja) | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤 |
WO2008093691A1 (ja) | 2007-01-31 | 2008-08-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | 網膜神経又は視神経の保護剤 |
WO2009103755A1 (en) * | 2008-02-19 | 2009-08-27 | Dsm Ip Assets B.V. | Novel use of 3,3'-diindolylmethane |
Non-Patent Citations (2)
Title |
---|
ARZNEIM.-FORSCH./DRUG RES., vol. 44, 1994, pages 344 - 348 |
See also references of EP2565196A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20130086143A (ko) | 2013-07-31 |
US20130005698A1 (en) | 2013-01-03 |
JPWO2011136161A1 (ja) | 2013-07-18 |
CN102884067A (zh) | 2013-01-16 |
EP2565196A1 (en) | 2013-03-06 |
EP2565196A4 (en) | 2014-03-26 |
AU2011246232A1 (en) | 2012-11-01 |
CA2791360A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3054952B1 (en) | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer | |
US20220387438A1 (en) | Calcineurin inhibitors of the setron family for the treatment of hearing loss | |
US20080255224A1 (en) | Pharmacological treatment of psoriasis | |
EP0778023B1 (en) | Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. | |
CA3222841A1 (en) | Use of atr inhibitors in combination with parp inhibitors for treating cancer | |
ES2886935T3 (es) | Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica | |
EP2110141B1 (en) | Protective agent for retinal nerve or optic nerve | |
NO309454B1 (no) | Anvendelse av et derivat av spirooksatiolankinuklidin for fremstilling av et farmasöytisk preparat for behandling av xerostomi som ikke er forårsaket av Sjögrens syndrom | |
US20110065754A1 (en) | Iminosugars and methods of treating filoviral diseases | |
HU207443B (en) | Method for producing medicine preparations serving for decreasing eye pressure containing imidazole derivatives | |
US20230028307A1 (en) | Treatment of neurological disorders with avermectins | |
CA3142842A1 (en) | Compositions and methods for treating central nervous system disorders | |
BG107185A (bg) | Метод за получаване на лекарствено средство за лечение на сексуална дисфункция с апоморфин при определени нива на плазмена концентрация | |
US20130281524A1 (en) | Novel treatments | |
CA2461625C (en) | Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension | |
MX2010012228A (es) | Estimuladores de sgc, activadores de sgc y combinaciones de los mismos para el tratamiento de la deficiencia auditiva. | |
WO2011136161A1 (ja) | 内耳障害の予防又は治療薬 | |
EP2982382A1 (en) | Compounds for preventing ototoxicity | |
US20040033946A1 (en) | Cell damage inhibitor | |
WO2014022291A1 (en) | Compounds reducing the production of sorbitol in the eye and methods of using the same | |
KR20230050363A (ko) | 질환의 치료에 있어서 btk 저해제의 용도 | |
US10463643B2 (en) | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea | |
US20070197593A1 (en) | Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver | |
US20120095052A1 (en) | Par-1 antagonism in fed or antacid-dosed patients | |
ITRM20110283A1 (it) | Vitamina b1 per uso nel trattamento della malattia celiaca e di malattie del sistema nervoso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180021301.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11774942 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2791360 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012512827 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13583707 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011246232 Country of ref document: AU Date of ref document: 20110425 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011774942 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127030432 Country of ref document: KR Kind code of ref document: A |